AAP
PGNX

Ardsley Advisory Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Ardsley Advisory Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-500,000
Closed -$2.1M – 156
2018
Q4 		$2.1M Hold
500,000
– – 0.53% 38
2018
Q3 		$3.13M Buy
500,000
+250,000
+100% +$1.92M 0.42% 46
2018
Q2 		$2.01M Buy
+250,000
New +$1.91M 0.3% 62

Other funds holding PGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Ardsley Advisory Partners's PGNX Position: Q3 2019 in Review

Ardsley Advisory Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 650,000 shares — an estimated $4.01M sold.

Ardsley Advisory Partners first reported a position in PGNX in Q2 2016 and held it in 13 quarters. The position peaked at $17.1M in Q2 2018. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Ardsley Advisory Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 650,000 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $4.01M.
  • Ardsley Advisory Partners first reported a position in Progenics Pharmaceuticals Inc in Q2 2016 and held it in 13 quarters.
  • Ardsley Advisory Partners's Progenics Pharmaceuticals Inc position peaked at $17.1M in Q2 2018.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Ardsley Advisory Partners's 13F filing for Q3 2019, filed 14 Nov 2019.